Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1247561.RApVEg2gb46W_oFj-VD5YgCly22gZfeKBO62wvlgqL5C0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1247561.RApVEg2gb46W_oFj-VD5YgCly22gZfeKBO62wvlgqL5C0130_assertion type Assertion NP1247561.RApVEg2gb46W_oFj-VD5YgCly22gZfeKBO62wvlgqL5C0130_head.
- NP1247561.RApVEg2gb46W_oFj-VD5YgCly22gZfeKBO62wvlgqL5C0130_assertion description "[In the present study, we used recombinant human p53 adenovirus (Ad-p53) and EGFR inhibitor gefitinib to treat the TNBC cell line MDA-MB-468.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1247561.RApVEg2gb46W_oFj-VD5YgCly22gZfeKBO62wvlgqL5C0130_provenance.
- NP1247561.RApVEg2gb46W_oFj-VD5YgCly22gZfeKBO62wvlgqL5C0130_assertion evidence source_evidence_literature NP1247561.RApVEg2gb46W_oFj-VD5YgCly22gZfeKBO62wvlgqL5C0130_provenance.
- NP1247561.RApVEg2gb46W_oFj-VD5YgCly22gZfeKBO62wvlgqL5C0130_assertion SIO_000772 25501339 NP1247561.RApVEg2gb46W_oFj-VD5YgCly22gZfeKBO62wvlgqL5C0130_provenance.
- NP1247561.RApVEg2gb46W_oFj-VD5YgCly22gZfeKBO62wvlgqL5C0130_assertion wasDerivedFrom befree-2016 NP1247561.RApVEg2gb46W_oFj-VD5YgCly22gZfeKBO62wvlgqL5C0130_provenance.
- NP1247561.RApVEg2gb46W_oFj-VD5YgCly22gZfeKBO62wvlgqL5C0130_assertion wasGeneratedBy ECO_0000203 NP1247561.RApVEg2gb46W_oFj-VD5YgCly22gZfeKBO62wvlgqL5C0130_provenance.